ArticleInternational journal of general medicine2026
Diagnostic Value of Serum CXCL2 and Fibronectin-1 in Acute Myocardial Infarction and Their Association with Neutrophil Extracellular Trap Formation.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Based on bioinformatics screening, C-X-C motif chemokine ligand 2 (CXCL2) and fibronectin 1 (FN1) were identified as common targets of acute myocardial infarction (AMI) and neutrophil extracellular traps (NETs). This study aimed to validate their adjunctive differential diagnostic value in emergency department patients with chest pain suspected of AMI, and explore NET associations. Methods: In this prospective observational study, 349 patients with chest pain suspected of AMI were enrolled between June 2022 and January 2025 and classified as non-AMI (n=226) or AMI (n=123). Serum CXCL2, FN1, and NETs biomarkers (myeloperoxidase-DNA [MPO-DNA] and citrullinated histone H3 [CitH3]) were measured by enzyme-linked immunosorbent assay (ELISA). Multivariable logistic regression, receiver operating characteristic (ROC) curves, and Spearman correlation were performed. Results: AMI patients had higher proportions of males, smokers, and angina, with elevated heart rate, fasting blood glucose (FBG), glycated hemoglobin (HbA1c), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), and reduced high-density lipoprotein cholesterol (HDL-C) versus non-AMI ( Conclusion: Serum CXCL2 and FN1 are elevated in AMI and correlate with NETs biomarkers. Combined detection demonstrated moderate diagnostic performance in patients with chest pain suspected of AMI, suggesting potential as novel auxiliary biomarkers for differential diagnosis in the ED. However, this single-center study had limited sample size and was positioned for differential diagnosis in symptomatic patients rather than asymptomatic screening. Multicenter, large-scale validation is needed to confirm reproducibility and generalizability, and functional studies (in vitro and in vivo) are required to clarify the mechanisms of NETs regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.